Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 29, 2024 - Accord BioPharma announced the FDA approval of Hercessi (trastuzumab-strf), biosimilar to Genentech’s Herceptin® (trastuzumab).
Download PDF
Return to publications
